ViaCyte, Inc., a leader in the emerging field of regenerative medicine, headquartered in San Diego, California, is developing a novel combination product for patients with insulin-requiring diabetes.  ViaCyte’s innovative VC-01™ product is based on the differentiation of stem cells into PEC-01™ pancreatic beta cell precursors, with subcutaneous implantation in the Encaptra® drug delivery system, a retrievable and immune-protective encapsulation medical device.  Once implanted, the precursor cells mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels.  ViaCyte’s goal is a product that can free patients with type 1 and type 2 diabetes from long-term insulin dependence.  ViaCyte has received substantial financial support from both the California Institute for Regenerative Medicine (CIRM) and JDRF.

Click to accept cookies and enable this content

Contact ViaCyte, Inc.
(858) 455-3708
info@ViaCyte.com
Visit Website